The ATP synthase inhibition induces an AMPK-dependent glycolytic switch of mesenchymal stem cells that enhances their immunotherapeutic potential

作者：Rafael Contreras‐López, Roberto Elizondo‐Vega, Noymar Luque‐Campos, Marı́a José Torres, Carolina Pradenas, Gautier Téjédor, María José Paredes-Martínez, Ana María Vega-Letter, Mauricio Campos‐Mora, Yandi Rigual-Gonzalez, Karina Oyarce, Magdiel Salgado, Christian Jørgensen, Maroun Khoury, María de los Ángeles García, Claudia Altamirano, Farida Djouad, Patricia Luz‐Crawford · 发表于：Theranostics · 年份：2020 · DOI：10.7150/thno.51631 · 被引用次数：69 · 研究领域：Mesenchymal stem cell research、Autophagy in Disease and Therapy、Epigenetics and DNA Methylation

Altogether, our findings show that AMPK-dependent glycolytic reprogramming of MSC using an ATP synthase inhibitor contributes to their immunosuppressive and therapeutic functions, and suggest that pro-glycolytic drugs might be used to improve MSC-based therapy.